Bioinvent International Ab Stock Current Liabilities
| BINV Stock | SEK 25.70 0.70 2.80% |
BioInvent International AB fundamentals help investors to digest information that contributes to BioInvent International's financial success or failures. It also enables traders to predict the movement of BioInvent Stock. The fundamental analysis module provides a way to measure BioInvent International's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioInvent International stock.
BioInvent |
BioInvent International AB Company Current Liabilities Analysis
BioInvent International's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current BioInvent International Current Liabilities | 28 M |
Most of BioInvent International's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioInvent International AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, BioInvent International AB has a Current Liabilities of 28 M. This is 98.4% lower than that of the Biotechnology sector and 94.84% lower than that of the Health Care industry. The current liabilities for all Sweden stocks is 99.65% higher than that of the company.
BioInvent Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioInvent International's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioInvent International could also be used in its relative valuation, which is a method of valuing BioInvent International by comparing valuation metrics of similar companies.BioInvent International is currently under evaluation in current liabilities category among its peers.
BioInvent Fundamentals
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 | |||
| Profit Margin | (0.14) % | |||
| Operating Margin | (0.16) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 65.8 M | |||
| Shares Owned By Insiders | 11.10 % | |||
| Shares Owned By Institutions | 57.02 % | |||
| Price To Earning | (9.49) X | |||
| Price To Book | 1.40 X | |||
| Price To Sales | 7.25 X | |||
| Revenue | 19.38 M | |||
| Gross Profit | 19.38 M | |||
| EBITDA | (263.32 M) | |||
| Net Income | (278.44 M) | |||
| Cash And Equivalents | 28.46 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 21.53 M | |||
| Debt To Equity | 22.00 % | |||
| Current Ratio | 2.73 X | |||
| Book Value Per Share | 25.92 X | |||
| Cash Flow From Operations | (245.84 M) | |||
| Earnings Per Share | (4.55) X | |||
| Target Price | 81.0 | |||
| Number Of Employees | 93 | |||
| Beta | 0.3 | |||
| Market Capitalization | 1.99 B | |||
| Total Asset | 1.45 B | |||
| Working Capital | 28 M | |||
| Current Asset | 56 M | |||
| Current Liabilities | 28 M | |||
| Z Score | 55.2 | |||
| Net Asset | 1.45 B |
About BioInvent International Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioInvent International AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioInvent International using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioInvent International AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioInvent Stock Analysis
When running BioInvent International's price analysis, check to measure BioInvent International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioInvent International is operating at the current time. Most of BioInvent International's value examination focuses on studying past and present price action to predict the probability of BioInvent International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioInvent International's price. Additionally, you may evaluate how the addition of BioInvent International to your portfolios can decrease your overall portfolio volatility.